Alternative use for hydrogel intrasaccular occlusion device with a spring for structural support
The present disclosure relates to the field of endovascular treatment. More particularly, the present invention uses a modified hydrogel intrasaccular occlusion device designed to implement an endovascular treatment to ameliorating or eliminating aneurysm recurrence, which hydrogel may optionally be impregnated with pharmaceutical compounds. The present invention also teaches the use of thin hydrogel coatings to ameliorate endovascular treatment related difficulties.
1. A device for ameliorating aneurysm recurrences by deploying amorphous hydrogel; said device further including:
a treatment mesh,
wherein said treatment mesh further includes a plurality of reinforcement elements,
said reinforcement elements comprising helically shaped springs of a preset coil length capable of straightening in a delivery-sheath catheter; and
wherein said reinforcement elements are wholly contained within said treatment mesh.
2. The device of claim 1 , wherein said amorphous hydrogel is impregnated with pharmaceutical compounds.
3. The device of claim 1 , wherein said device comprises a thin coating of amorphous hydrogel on any surface exposed to blood or a lumen wall.
4. A device for ameliorating vascular outpouchings by deploying a treatment mesh,
wherein said treatment mesh further includes a plurality of reinforcement elements, said reinforcement elements comprising helically shaped springs of a preset coil length capable of straightening in a delivery-sheath catheter;
and wherein said reinforcement elements are wholly contained within said treatment mesh.
5. A device for ameliorating vascular outpouchings by deploying amorphous hydrogel; said device further including:
a treatment mesh,
wherein said treatment mesh further includes a plurality of reinforcement elements, said reinforcement elements comprising helically shaped springs of a preset coil length capable of straightening in a delivery-sheath catheter, and
wherein said reinforcement elements are wholly contained within said treatment mesh.
6. The device of claim 5 , wherein said amorphous hydrogel is impregnated with pharmaceutical compounds.
7. The device of claim 5 , wherein said device comprises a thin coating of said amorphous hydrogel on any surface exposed to blood or a lumen wall.